Zealand Pharma A/S (ZLDPF) – What Are Researchers Thinking About This Stock?

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned an average rating of “Hold” from the eleven analysts that are covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have assigned a strong buy recommendation to the company.

Several brokerages have commented on ZLDPF. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Finally, Zacks Research raised Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $33.39 on Tuesday. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of 5.54 and a beta of 0.95. The firm has a fifty day moving average price of $44.12 and a 200 day moving average price of $45.83. Zealand Pharma A/S has a fifty-two week low of $33.39 and a fifty-two week high of $83.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.